# A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

> **NCT01413503** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 50 (actual)

## Conditions studied

- Pheochromocytoma
- Paraganglioma

## Interventions

- **RADIATION:** 131I-MIBG

## Key facts

- **NCT ID:** NCT01413503
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1991-05
- **Primary completion:** 2007-09-06
- **Final completion:** 2009-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01413503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01413503, "A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01413503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*